Sarepta Therapeutics Appoints Stephen L. Mayo, Ph.D., to its Board of Directors
- A renowned expert in protein engineering, Dr. Mayo brings extensive scientific expertise and strong business acumen to the Company’s board
CAMBRIDGE, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) — Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Stephen L. Mayo, Ph.D., to its Board of Directors, effective immediately. Dr. Mayo is currently the Bren Professor of Biology and Chemistry at California Institute of Technology (Caltech), and serves on the board of directors for Merck and on the scientific advisory board of Rubryc Therapeutics.
“We are delighted to welcome Dr. Mayo to the Sarepta Board of Directors. A world-renowned expert in protein engineering, he will bring significant scientific and business acumen to our board as Sarepta advances its industry leading pipeline of genetic medicines,” said M. Kathleen Behrens, Ph.D., Chairperson of Sarepta’s Board of Directors.
“A trailblazer in science and academia, Dr. Mayo’s impressive track record of scientific achievement and business success will be vital as we work to deliver on the promise of our pipeline and change the model for treating individuals with rare disease,” said Doug Ingram, Sarepta’s president and chief executive officer.
“Sarepta is at the forefront of a transformative era in genetic medicine and their multi-platform approach across RNA, gene therapy, and gene editing is particularly exciting. It is an honor to join the board at this pivotal juncture,” said Dr. Mayo. “I look forward to working with the Sarepta team and contributing in a meaningful way to the Company’s mission, growth and continued success on behalf of patients.”
At Caltech, Dr. Mayo holds joint appointments in the Division of Biology and Biological Engineering and the Division of Chemistry and Chemical Engineering. He joined the Caltech faculty in 1992 and served as Vice Provost for Research from 2007 to 2010 and Chair of the Division of Biology and Biological Engineering from 2010 to 2020. Dr. Mayo’s research focuses on the development of computational approaches to protein engineering – a field that has broad applications ranging from advanced biofuels to human therapeutics. In 2004, he was elected to the U.S. National Academy of Sciences for his pioneering contributions in the field of protein design.
Dr. Mayo has co-founded several companies: Molecular Simulations Inc. (now Biovia), Xencor, and Protabit, where he serves on the scientific advisory board. In addition to his academic and private-sector work, Dr. Mayo has served as an elected Board Member at the American Association for the Advancement of Science (2010-2014) and served as a presidential appointee to National Science Foundation’s National Science Board (2013-2018).
Dr. Mayo received an undergraduate degree in chemistry from the Pennsylvania State University, and a Ph.D. in chemistry from Caltech. He completed postdoctoral work at both UC Berkeley and the Stanford University School of Medicine.
About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit www.sarepta.com or follow us on Twitter, LinkedIn, Instagram and Facebook.
Internet Posting of Information
We routinely post information that may be important to investors in the ‘For Investors’ section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Forward-Looking Statements
This press release contains forward-looking statements. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “will,” “intends,” “potential,” “possible” and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements regarding the potential of Sarepta to advance its industry leading pipeline of genetic medicines and the expectation that Dr. Mayo’s scientific and business acumen will be vital to Sarepta as Sarepta works to deliver on the promise of its pipeline and change the model for treating individuals with rare disease.
These forward-looking statements involve risks and uncertainties, many of which are beyond Sarepta’s control. Known risk factors include, among others: Sarepta may not be able to execute on its business plans, including meeting its expected or planned regulatory milestones and timelines, clinical development plans, and bringing its products to U.S. and ex-U.S. markets for various reasons including possible limitations of Company financial and other resources, manufacturing limitations that may not be anticipated or resolved for in a timely manner, and regulatory, court or agency decisions, such as decisions by the United States Patent and Trademark Office with respect to patents that cover Sarepta’s product candidates; and those risks identified under the heading “Risk Factors” in Sarepta’s most recent Annual Report on Form 10-K for the year ended December 31, 2020, and most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company which you are encouraged to review.
Any of the foregoing risks could materially and adversely affect the Company’s business, results of operations and the trading price of Sarepta’s common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review the SEC filings made by Sarepta. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except as required by law.
Source: Sarepta Therapeutics, Inc.
Investor Contact:
Ian Estepan, 617-274-4052
iestepan@sarepta.com
Media Contact:
Tracy Sorrentino, 617-301-8566
tsorrentino@sarepta.com
